Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.

Related Articles

Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.

Ocul Immunol Inflamm. 2017 Apr;25(2):229-232

Authors: Uzun A, Yalcindag FN, Demirel S, Batýoðlu F, Ozmert E

Abstract
PURPOSE: To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).
METHODS: In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).
RESULTS: The mean anterior chamber flare was 10.7 ± 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 ± 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 ± 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).
CONCLUSIONS: No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.

PMID: 26828124 [PubMed - indexed for MEDLINE]

http://ift.tt/2CKyWwX